cholecalciferol has been researched along with Respiratory-Tract-Diseases* in 3 studies
2 review(s) available for cholecalciferol and Respiratory-Tract-Diseases
Article | Year |
---|---|
[Vitamin D and coronavirus: a new field of use?]
Given the succession of communications in scientific and popular circuits, tending to take for granted a role for vitamin D in the control of the coronavirus pandemic, the authors conducted an analysis of the literature currently available in order to recognize what is supported by opinions personal and what evidence of effectiveness. At the end of the bibliographic survey there is the current absence of evidence of efficacy in favor of vitamin D in the treatment of coronavirus infection in its various expressions. The diffusion of personal opinions as if they were evidence can be a disturbing factor for adequate assistance and for correct research. Topics: Betacoronavirus; Calcifediol; Cholecalciferol; Coronavirus Infections; COVID-19; Evidence-Based Medicine; Humans; Pandemics; Pneumonia, Viral; Respiratory Tract Diseases; SARS-CoV-2; Vitamin D; Vitamin D Deficiency; Vitamins | 2020 |
Beneficial role of vitamin D3 in the prevention of certain respiratory diseases.
There is evidence of aberrations in the vitamin D-endocrine system in subjects with respiratory diseases. Vitamin D deficiency is highly prevalent in patients with respiratory diseases, and patients who receive vitamin D have significantly larger improvements in inspiratory muscle strength and maximal oxygen uptake. Studies have provided an opportunity to determine which proteins link vitamin D to respiratory pathology, including the major histocompatibility complex class II molecules, vitamin D receptor, vitamin D-binding protein, chromosome P450, Toll-like receptors, poly(ADP-ribose) polymerase-1, and the reduced form of nicotinamide adenine dinucleotide phosphate. Vitamin D also exerts its effect on respiratory diseases through cell signaling mechanisms, including matrix metalloproteinases, mitogen-activated protein kinase pathways, the Wnt/β-catenin signaling pathway, prostaglandins, reactive oxygen species, and nitric oxide synthase. In conclusion, vitamin D plays a significant role in respiratory diseases. The best form of vitamin D for use in the treatment of respiratory diseases is calcitriol because it is the active metabolite of vitamin D3 and modulates inflammatory cytokine expression. Further investigation of calcitriol in respiratory diseases is needed. Topics: Animals; Calcitriol; Cholecalciferol; Cytokines; Humans; Muscle Strength; Oxygen Consumption; Prevalence; Respiratory Tract Diseases; Signal Transduction; Vitamin D; Vitamin D Deficiency | 2013 |
1 trial(s) available for cholecalciferol and Respiratory-Tract-Diseases
Article | Year |
---|---|
The effect of vitamin D administration on vitamin D status and respiratory morbidity in late premature infants.
To assess whether increment of vitamin D daily intake results in improved serum25(OH) vitamin D levels and reduced respiratory morbidity in premature infants.. A randomized double-blind clinical pilot trial, including preterm infants born at 32 + 6 to 36 + 6 weeks of gestation. The control group received 400 international units (IU) of cholecalciferol daily compared to 800 IU daily in the intervention group. Levels of 25(OH) vitamin D were measured at birth and 6 and 12 months of age. Respiratory morbidity was followed until 1 year of age.. Fifty subjects were recruited during the study period; the median measured 25(OH) vitamin D levels in the control vs intervention groups were: 26.5 vs 34 nmol/L (P = .271) at birth, 99 vs 75.5 nmol/L (P = .008) at 6 months and 72.5 vs 75 nmol/L (P = .95) at 12 months of age. Infants with insufficient vitamin D (<75 nmol/L) levels had higher respiratory morbidity. Serum vitamin 25(OH) D is a fair predictor for respiratory symptoms (area under the curve [AUC], 0.697; 95% confidence interval [CI], 0.509-0.885; P = .047) and for recorded acute respiratory illnesses (AUC, 0.745; 95% CI, 0.569-0.922; P = .012).. Doubling the daily intake of vitamin D in premature infants did not increase serum 25(OH) vitamin D level, due to poor compliance in the intervention group. We found an inverse association between serum 25(OH) vitamin D and respiratory symptoms, indicating vitamin D deficiency is a fair predictor for respiratory morbidity. Topics: Cholecalciferol; Dietary Supplements; Double-Blind Method; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Male; Morbidity; Pilot Projects; Respiratory Tract Diseases; Vitamin D Deficiency; Vitamins | 2020 |